This approval represents a significant regulatory milestone, making Prolivâ„¢Rx the first and only at-home neuromodulation treatment with FDA labeling applicable to treatment refractory MDD patients.
The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results